Cargando…
The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue mai...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210184/ https://www.ncbi.nlm.nih.gov/pubmed/25347196 http://dx.doi.org/10.1371/journal.pone.0111336 |
_version_ | 1782341339793326080 |
---|---|
author | Spenlé, Caroline Lefebvre, Olivier Lacroute, Joël Méchine-Neuville, Agnès Barreau, Frédérick Blottière, Hervé M. Duclos, Bernard Arnold, Christiane Hussenet, Thomas Hemmerlé, Joseph Gullberg, Donald Kedinger, Michèle Sorokin, Lydia Orend, Gertraud Simon-Assmann, Patricia |
author_facet | Spenlé, Caroline Lefebvre, Olivier Lacroute, Joël Méchine-Neuville, Agnès Barreau, Frédérick Blottière, Hervé M. Duclos, Bernard Arnold, Christiane Hussenet, Thomas Hemmerlé, Joseph Gullberg, Donald Kedinger, Michèle Sorokin, Lydia Orend, Gertraud Simon-Assmann, Patricia |
author_sort | Spenlé, Caroline |
collection | PubMed |
description | Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue maintenance, and in cancer progression which represents an inherent risk of IBD. Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chains are specifically and ectopically overexpressed with a concomitant nuclear p53 accumulation. Linked to this observation, we provided a mechanism showing that p53 induces LMα1 expression at the promoter level by ChIP analysis and this was confirmed by knockdown in cell transfection experiments. To mimic the human disease, we induced colitis and colitis-associated cancer by chemical treatment (DSS) combined or not with a carcinogen (AOM) in transgenic mice overexpressing LMα1 or LMα5 specifically in the intestine. We demonstrated that high LMα1 or LMα5 expression decreased susceptibility towards experimentally DSS-induced colon inflammation as assessed by histological scoring and decrease of pro-inflammatory cytokines. Yet in a pro-oncogenic context, we showed that LM would favor tumorigenesis as revealed by enhanced tumor lesion formation in both LM transgenic mice. Altogether, our results showed that nuclear p53 and associated overexpression of LMα1 and LMα5 protect tissue from inflammation. But in a mutation setting, the same LM molecules favor progression of IBD into colitis-associated cancer. Our transgenic mice represent attractive new models to acquire knowledge about the paradoxical effect of LM that mediate either tissue reparation or cancer according to the microenvironment. In the early phases of IBD, reinforcing basement membrane stability/organization could be a promising therapeutic approach. |
format | Online Article Text |
id | pubmed-4210184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42101842014-10-30 The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? Spenlé, Caroline Lefebvre, Olivier Lacroute, Joël Méchine-Neuville, Agnès Barreau, Frédérick Blottière, Hervé M. Duclos, Bernard Arnold, Christiane Hussenet, Thomas Hemmerlé, Joseph Gullberg, Donald Kedinger, Michèle Sorokin, Lydia Orend, Gertraud Simon-Assmann, Patricia PLoS One Research Article Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue maintenance, and in cancer progression which represents an inherent risk of IBD. Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chains are specifically and ectopically overexpressed with a concomitant nuclear p53 accumulation. Linked to this observation, we provided a mechanism showing that p53 induces LMα1 expression at the promoter level by ChIP analysis and this was confirmed by knockdown in cell transfection experiments. To mimic the human disease, we induced colitis and colitis-associated cancer by chemical treatment (DSS) combined or not with a carcinogen (AOM) in transgenic mice overexpressing LMα1 or LMα5 specifically in the intestine. We demonstrated that high LMα1 or LMα5 expression decreased susceptibility towards experimentally DSS-induced colon inflammation as assessed by histological scoring and decrease of pro-inflammatory cytokines. Yet in a pro-oncogenic context, we showed that LM would favor tumorigenesis as revealed by enhanced tumor lesion formation in both LM transgenic mice. Altogether, our results showed that nuclear p53 and associated overexpression of LMα1 and LMα5 protect tissue from inflammation. But in a mutation setting, the same LM molecules favor progression of IBD into colitis-associated cancer. Our transgenic mice represent attractive new models to acquire knowledge about the paradoxical effect of LM that mediate either tissue reparation or cancer according to the microenvironment. In the early phases of IBD, reinforcing basement membrane stability/organization could be a promising therapeutic approach. Public Library of Science 2014-10-27 /pmc/articles/PMC4210184/ /pubmed/25347196 http://dx.doi.org/10.1371/journal.pone.0111336 Text en © 2014 Spenlé et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Spenlé, Caroline Lefebvre, Olivier Lacroute, Joël Méchine-Neuville, Agnès Barreau, Frédérick Blottière, Hervé M. Duclos, Bernard Arnold, Christiane Hussenet, Thomas Hemmerlé, Joseph Gullberg, Donald Kedinger, Michèle Sorokin, Lydia Orend, Gertraud Simon-Assmann, Patricia The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title | The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title_full | The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title_fullStr | The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title_full_unstemmed | The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title_short | The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? |
title_sort | laminin response in inflammatory bowel disease: protection or malignancy? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210184/ https://www.ncbi.nlm.nih.gov/pubmed/25347196 http://dx.doi.org/10.1371/journal.pone.0111336 |
work_keys_str_mv | AT spenlecaroline thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT lefebvreolivier thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT lacroutejoel thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT mechineneuvilleagnes thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT barreaufrederick thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT blottierehervem thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT duclosbernard thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT arnoldchristiane thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT hussenetthomas thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT hemmerlejoseph thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT gullbergdonald thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT kedingermichele thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT sorokinlydia thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT orendgertraud thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT simonassmannpatricia thelamininresponseininflammatoryboweldiseaseprotectionormalignancy AT spenlecaroline lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT lefebvreolivier lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT lacroutejoel lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT mechineneuvilleagnes lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT barreaufrederick lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT blottierehervem lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT duclosbernard lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT arnoldchristiane lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT hussenetthomas lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT hemmerlejoseph lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT gullbergdonald lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT kedingermichele lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT sorokinlydia lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT orendgertraud lamininresponseininflammatoryboweldiseaseprotectionormalignancy AT simonassmannpatricia lamininresponseininflammatoryboweldiseaseprotectionormalignancy |